Get notified when AVR files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsAnteris exits v2vmedtech partnership, pays $400k break fee; equity stake may be bought back
Filed April 29, 2026 · Period ending April 29, 2026 · ~1 min read
Key Changes
-
high
Anteris terminated its 2023 development agreement with v2vmedtech after completing Stage 1, ending all future development contributions and operational ties to the partnership.
Item 1.01 view on EDGAR → -
high
v2vmedtech's original shareholders can either buy out Anteris' entire equity stake at cost or dilute the company to a capped minority position; the choice and financial impact remain undisclosed.
Item 1.01 view on EDGAR → -
medium
Anteris will pay a one-time $400,000 break fee to v2vmedtech, which will use the funds to continue developing the technology independently.
Item 1.01 view on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (CAG 10-K) is open in full — no account needed.
Partner
Trade AVR commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify